Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the first
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2016-- Aimmune Therapeutics , Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized  O ral  D esensitization  I mmuno T herapy) treatments for life-threatening food allergies, today announced that Stephen G.
Toggle Summary Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101
— Aimmune Discussed Phase 2 Data, Including Peanut-Specific IgE Values, at FARE Research Retreat — BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy)
Toggle Summary Aimmune Therapeutics Appoints Douglas Sheehy as General Counsel and Secretary
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 5, 2016-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced the appointment of Douglas Sheehy as General
Toggle Summary Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
— All Patients Who Completed 12 Weeks of Low-Dose Maintenance Therapy in the ARC002 Trial Were Desensitized to Levels of Peanut Protein Far Exceeding Those of Typical Accidental Exposures — — Dr. J. Andrew Bird Presented Data Confirming Safety and Demonstrating Efficacy of AR101 for the Treatment
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
─ Company Began 2016 with Approximately $200 Million in Cash and Investments and Its Phase 3 PALISADE Trial Underway for Peanut Allergic Patients ─ ─ Late-Breaker Presentation on New AR101 Phase 2 Data This Sunday at AAAAI ─ ─ Conference Call and Webcast Today at 5 p.m. Eastern Time / 2 p.m.
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
─ Cowen and Company 36 th Annual Health Care Conference ─ ─ Barclays Capital Global Healthcare Conference ─ ─ Webcasts Available Through Aimmune Corporate Website ─ BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 1, 2016-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016
— Webcast and Conference Call to Follow — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 25, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that its financial results for the fourth quarter and full
Toggle Summary Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Aimmune Late-Breaking Abstract Posted Online Today by The Journal of Allergy and Clinical Immunology (JACI) — — Dr. J. Andrew Bird Will Present Data on the Efficacy and Safety of AR101 for the Treatment of Peanut Allergy from the ARC002 Phase 2 Follow-On Trial — BRISBANE, Calif.
Toggle Summary Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
— Presentation on Monday, February 8, 2016 , at 9:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly , M.B.B.S., Ph.D.,